Nuvectis Pharma (NVCT)
(Delayed Data from NSDQ)
$6.46 USD
+0.16 (2.54%)
Updated Aug 13, 2024 04:00 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Brokerage Reports
Nuvectis Pharma, Inc. [NVCT]
Reports for Purchase
Showing records 61 - 68 ( 68 total )
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; Asset Profiles Continue to Strengthen; NXP-800 Phase 1 Progressing as Planned; PT Upped to $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage with a Buy rating and a 12-month price target of $20
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Data Continues to Untangle Mechanisms of NXP-900 Sensitivity at AACR
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
AACR Preclinical Data Underscores NXP-800''s Activity Towards ARID1A Mutant Tumors
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Nature Article by AstraZeneca Places Nice Focus on NXP-900 Potential to Overcoming EGFR Resistance in NSCLC
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
2021 Results; Early Stage Pipeline Prepares For Takeoff; NXP800 Data Expected Throughout 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Nuvectis Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Early Yet Precise Approach to Oncology; Initiating at Buy; $14 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J